Unicycive Therapeutics Inc
UNCY6.180USD
+0.060+0.98%
收盤 01/09, 16:00（美東）報價延遲15分鐘
128.86M總市值
虧損本益比TTM
關於 Unicycive Therapeutics Inc 公司
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc簡介
公司代碼UNCY
公司名稱Unicycive Therapeutics Inc
上市日期Jun 17, 2021
CEOGupta (Shalabh)
員工數量22
證券類型Ordinary Share
年結日Jun 17
公司地址4300 El Camino Real, Suite 210
城市LOS ALTOS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94022
電話16503840642
網址https://unicycive.com/
公司代碼UNCY
上市日期Jun 17, 2021
CEOGupta (Shalabh)
Unicycive Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Vivo Capital, LLC
8.33%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
The Vanguard Group, Inc.
3.07%
其他
75.88%
持股股東
持股股東
佔比
Vivo Capital, LLC
8.33%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
The Vanguard Group, Inc.
3.07%
其他
75.88%
股東類型
持股股東
佔比
Hedge Fund
14.44%
Venture Capital
10.71%
Investment Advisor
3.40%
Individual Investor
2.93%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.29%
其他
66.69%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
65
6.53M
30.38%
-306.64K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Vivo Capital, LLC
1.79M
8.33%
+652.90K
+57.42%
Sep 30, 2025
Octagon Capital Advisors LP
1.00M
4.65%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
939.20K
4.37%
--
--
Sep 30, 2025
Great Point Partners, LLC
796.56K
3.71%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
658.88K
3.07%
+52.92K
+8.73%
Sep 30, 2025
Gupta (Shalabh K)
597.25K
2.78%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
2.2%
+1.00
+0.00%
Sep 30, 2025
Rosalind Advisors, Inc.
242.49K
1.13%
+242.49K
--
Apr 30, 2025
Geode Capital Management, L.L.C.
125.73K
0.58%
+66.94K
+113.87%
Sep 30, 2025
Squarepoint Capital LLP
117.33K
0.55%
+117.33K
--
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 17, 2025
Merger
10→1
公告日期
類型
比率
Jun 17, 2025
Merger
10→1
常見問題
Unicycive Therapeutics Inc的前五大股東是誰？
Unicycive Therapeutics Inc的前五大股東如下：
Vivo Capital, LLC持有股份：1.79M佔總股份比例：8.33%。
Octagon Capital Advisors LP持有股份：1.00M佔總股份比例：4.65%。
Nantahala Capital Management, LLC持有股份：939.20K佔總股份比例：4.37%。
Great Point Partners, LLC持有股份：796.56K佔總股份比例：3.71%。
The Vanguard Group, Inc.持有股份：658.88K佔總股份比例：3.07%。
Vivo Capital, LLC持有股份：1.79M佔總股份比例：8.33%。
Octagon Capital Advisors LP持有股份：1.00M佔總股份比例：4.65%。
Nantahala Capital Management, LLC持有股份：939.20K佔總股份比例：4.37%。
Great Point Partners, LLC持有股份：796.56K佔總股份比例：3.71%。
The Vanguard Group, Inc.持有股份：658.88K佔總股份比例：3.07%。
Unicycive Therapeutics Inc的前三大股東類型是什麼？
Unicycive Therapeutics Inc 的前三大股東類型分別是：
Vivo Capital, LLC
Octagon Capital Advisors LP
Nantahala Capital Management, LLC
Vivo Capital, LLC
Octagon Capital Advisors LP
Nantahala Capital Management, LLC
有多少機構持有Unicycive Therapeutics Inc(UNCY)的股份？
截至2025Q4，共有65家機構持有Unicycive Therapeutics Inc的股份，合計持有的股份價值約為6.53M，占公司總股份的30.38% 。與2025Q3相比，機構持股有所增加，增幅為-1.00%。
哪個業務部門對Unicycive Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Unicycive Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
